Summarized by Masters of Longevity from PR Newswire.
Preclinical data show a co-formulated peptide combination produced marked weight loss, strong stability, and ultra-long pharmacokinetics supporting infrequent dosing schedules.
Key Takeaways
- ASC36_35FDC produced 24.8% body-weight reduction in DIO rats versus 16.8% and 12.5% for two comparator co-formulations.
- No fibril-induced aggregation was observed for ASC36_35FDC under simulated storage, while cagrilintide showed substantial aggregation.
- ASC36 and ASC35 in the combination showed half-lives of about 33 and 30 days in NHPs, supporting monthly to potentially quarterly dosing.
